Pacific Biosciences of California, Inc.

In an effort to push the boundaries of molecular biology, our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Harnessing advances in biochemistry, optics, nanofabrication, and more, we developed Single Molecule, Real-Time (SMRT) Sequencing technology. This powerful technology transforms the understanding of biological systems by enabling real-time analysis of biomolecules with single-molecule resolution.PacBio sequencing offers the most comprehensive view of genomes, transcriptomes, and epigenomes — including the full spectrum of genetic variation — by providing the longest average read lengths, highest consensus accuracy, and most uniform coverage of any sequencing technology on the market today. Ideal for de novo genome assembly and genetic variation characterization of humans, animals, plants, and microbes, this system features high-performance optics, automated liquid handling, and an intuitive, intelligent operating system.We are passionate about developing high-quality, innovative technologies and systems that impact areas of critical importance, including the diagnosis and treatment of disease and efforts to improve the world’s food and energy supply. We believe that our tools will lead to advances that will create long-lasting benefits for the world and its future.

Bank Name Pacific Biosciences of California, Inc.
Stock Exchange NASDAQ
Symbol PACB
Sector Healthcare
Industry Biotechnology: Laboratory Analytical Instruments
Country United States
World Region Amarica
Chairman Dr. Michael W. Hunkapiller
CEO Dr. Michael W. Hunkapiller
Employees 456
Website www.pacb.com
Registered Year 2000

 

UpdateContent
UpdateContent
UpdateContent